Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: Methodological Concerns
JACC: Advances
· Elsevier
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Читать у издателя →
Цитирование
Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: Methodological Concerns. // JACC: Advances. – URL: https://www.sciencedirect.com/science/article/pii/S2772963X26008240?dgcid=rss_sd_all
Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: Methodological Concerns. JACC: Advances. https://www.sciencedirect.com/science/article/pii/S2772963X26008240?dgcid=rss_sd_all
“Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: Methodological Concerns.” JACC: Advances.
@article{article50596,
title = {Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: Methodological Concerns},
journal = {JACC: Advances},
url = {https://www.sciencedirect.com/science/article/pii/S2772963X26008240?dgcid=rss_sd_all}
}